Ascendis to present 2-year achondroplasia trial data at ISDS

Copenhagen, Denmark - Ascendis Pharma A/S, a company listed on the NASDAQ stock exchange, will be unveiling results from a two-year clinical trial of its product, YUVIWEL, at an upcoming medical conference. The trial, known as ApproaCH, focused on the effects of once-weekly administration of TransCon CNP in children suffering from achondroplasia, a condition that affects skeletal development.

Dr. Carlos Bacino, a distinguished professor from Baylor College of Medicine, will be leading the discussion on Friday morning. His presentation is scheduled during a session dedicated to the International Skeletal Dysplasia Society, an organization that specializes in studying rare skeletal conditions. The data presented will come from the open-label extension phase of the trial, which provides a more detailed look at the drug's effects over an extended period.

Ascendis is currently seeking approval from the European Medicines Agency for its Marketing Authorization Application of YUVIWEL. If granted, the drug could soon become available across Europe. YUVIWEL contains a prodrug version of C-type natriuretic peptide, a substance that works by counteracting the overactive signaling of the fibroblast growth factor receptor 3, a genetic mutation associated with achondroplasia.

Achondroplasia is a rare condition, impacting more than 250,000 individuals globally. It can cause a range of health issues, including spinal deformities, brain enlargement, reduced muscle strength, hearing loss, breathing problems, and persistent pain. In addition to the main presentation, Ascendis will also share a poster at the conference, analyzing the potential for injection site reactions when using their drug versus other treatments.

The company's headquarters are based in Copenhagen, with additional operations in Europe and the United States.